# Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.

> **NCT00731224** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 380 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Rivastigmine transdermal patch

## Key facts

- **NCT ID:** NCT00731224
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 380 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00731224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00731224, "Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00731224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*